This study looks at how safe it is to add a drug called melphalan, injected directly into the eye, to standard chemotherapy to treat retinoblastoma, a type of eye cancer. Retinoblastoma can be harder to treat when there are tumors in the eye's fluid. The study aims to see if adding melphalan at the start could help. Melphalan works by damaging the DNA in cancer cells to stop them from growing. Other drugs used in the study are carboplatin, vincristine, and etoposide, which all help kill or slow cancer cells in different ways.

• The study lasts for several cycles, with each cycle lasting 28 days.
• Participants will receive up to 6 cycles of treatment and may require regular eye exams under anesthesia.
• Participants must be younger than 18 and meet specific health criteria.

Participants will be closely monitored with follow-ups for up to 5 years. This study is important for finding better ways to treat this form of cancer, especially for those with vitreous seeds. All participants need parental consent and must meet health and legal requirements.